INBX stock steadies near $120 as losses widen in latest quarter
Published on 08/29/2026 at 10:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Inhibrx Biosciences, Inc. (INBX, ISIN US45720L1070) stock is trading in the low-$120 range as of August 28, 2026, with the clinical-stage biotech still posting steep losses in its most recent reported quarter.
Latest earnings show deeper losses
Inhibrx Biosciences last reported quarterly earnings on August 13, 2026, and the company posted a loss per share of $2.34 for that period, missing the consensus estimate loss of $2.28 by $0.06.
For the current full year 2026, analyst models compiled in the latest overview point to a projected loss of $9.91 per share, highlighting how far the company remains from breakeven even after its recent corporate restructuring.
INBX stock price and recent trading range
Recent quote data as of August 28, 2026, shows INBX stock trading at $120.54, representing a single-day decline of 2.74% and confirming that the shares have eased back from the prior session level of $123.93 that had been recorded earlier in the week.
Intraday data from the US market close on August 28, 2026, also places INBX in the mid-$120s, with market activity illustrating how the stock can move several percentage points in a single session as the market digests ongoing news around its biologic pipeline and cash burn trajectory.
Biotech pipeline and product focus
Inhibrx Biosciences operates as a clinical-stage biopharmaceutical company developing a pipeline of novel biologic therapeutic candidates built on proprietary modular protein engineering platforms, targeting serious diseases where existing treatments leave significant unmet medical need.
INBX shares and market context
With INBX stock near $120.54 as of August 28, 2026, investors are weighing the company’s high potential pipeline against a full-year 2026 loss forecast of $9.91 per share and the recent quarterly loss of $2.34, both of which emphasize the speculative nature of the shares.
Company fact box
Company: Inhibrx Biosciences, Inc.
ISIN: US45720L1070
Ticker: INBX
Exchange: Nasdaq
